About this visual
Joe’s announcement-day visual on oral orforglipron, formulation, and dosing.
Sources & further reading
Original LinkedIn post and discussion ↗
Additional references appear in the infographic and the original LinkedIn discussion.

Originally posted Apr 2026 · By Joe Zucchi, PA-C, MPAS
1280 × 713 px · PDF includes the original image and a link to this page.
Joe’s announcement-day visual on oral orforglipron, formulation, and dosing.
Original LinkedIn post and discussion ↗
Additional references appear in the infographic and the original LinkedIn discussion.

Medication plus lifestyle support, viewed alongside the placebo arms of major trials.

A dated side-by-side overview of trial efficacy and approximate cash-pay pricing.

A March 2026 visual covering the STEP UP trial and higher-dose semaglutide.
Big news in obesity medicine today: the FDA has approved Foundayo (orforglipron), Eli Lilly’s once-daily oral GLP-1 for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity.
A few important points that stand out:
Foundayo is a tablet taken once daily, and it does not need to be taken on an empty stomach or with food/water restrictions.
The FDA-approved titration starts at 0.8 mg daily, then increases to 2.5 mg after at least 30 days, then 5.5 mg after another 30 days. Based on response and tolerability, it can then be escalated stepwise to 9 mg, 14.5 mg, or 17.2 mg.
For anyone wondering why those numbers look different from the ATTAIN obesity trials, that is an important formulation detail: the ATTAIN program used capsules with target maintenance doses of 6 mg, 12 mg, and 36 mg, while the FDA-approved commercial product is a tablet.
Lilly ran a dedicated tablet versus capsule pharmacokinetic study to compare exposure between the two formulations. Publicly available Lilly patent data appear to show very close steady-state exposure matching between the capsule and tablet pairs, including:
1 mg capsule -> 0.8 mg tablet
3 mg capsule -> 2.5 mg tablet
6 mg capsule -> 5.5 mg tablet
12 mg capsule -> 9 mg tablet
24 mg capsule -> 14.5 mg tablet
36 mg capsule -> 17.2 mg tablet
That helps explain why the approved tablet strengths do not mirror the original trial capsule doses one-for-one.
The FDA notes that approval was supported by two randomized, double-blind, placebo-controlled 72-week trials, and Lilly highlighted that the highest dose in ATTAIN-1 produced average weight loss of 27.3 pounds, or 12.4%, among those who remained on treatment.
This is another step forward for obesity care! Available through LillyDirect starting April 6, with self-pay pricing beginning at $149 for the lowest dose.
Update on pricing: LillyDirect is now listing Foundayo self-pay pricing by dose at $149/month for 0.8 mg, $199/month for 2.5 mg, $299/month for 5.5 mg and 9 mg, and $299/month for 14.5 mg and 17.2 mg when refilled within 45 days. Lilly notes that the regular price for the 14.5 mg and 17.2 mg doses is $349/month if not refilled within that 45-day window.
Check out the infographic I made for more info. Links in the comments.